A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

This Phase 1 study is evaluating how the body absorbs and processes a new experimental weight-loss medication called ABBV-295 given as a subcutaneous (under-the-skin) injection in women with overweight or obesity who are also taking oral contraceptives. The main focus is understanding drug levels in the body and monitoring safety, not weight loss outcomes at this stage. You may be eligible if you are a woman with a BMI between 25 and 35, not pregnant or breastfeeding, and not currently taking other weight-loss medications or enrolled in an obesity trial; stable weight in the past 3 months is also required. Participation involves receiving injections as assigned and attending clinic visits for blood tests and safety monitoring. This summary was prepared using AI to help patients understand this research.